Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)

8:00

Breakfast in Lobby

8:30

Salvatore Sechi, PhD

NIDDK/NIH

History and Purpose of TaMADOR

8:45

Des Schatz, MD

University of Florida

Clinical Trials and Biomarkers

9:20

Cate Speake, PhD

Benaroya Research Institute

Biomarkers in Type 1 Diabetes Research

9:55

Jenny Van Eyk, PhD

Cedars-Sinai (Virtual)

Assessment of Obesity and Diabetes as Co-morbidities in Precision Health

10:20

Coffee Break in Lobby

10:30

Andy Hoofnagle, MD, PhD

University of Washington

The TaMADOR Consortium: Interlaboratory Transfer of a Combined Antibody-free Insulin/C-peptide Assay

10:55

Jessica Becker, MLS (ASCP), MS

University of Washington

Preparing for the Interlaboratory Transfer of a Novel Assay to Measure Glucagon and Oxyntomodulin

11:20

Weijun Qian, PhD

PNNL

LC-MS Assays for Specific Prohormone Proteoforms (Insulin and IAPP) Relevant to Type 1 Diabetes

11:45

Sara Shijo

University of Washington

Progress Toward a Proteolysis-peptide Immunoaffinity Enrichment-LC-MS/MS Assay for Proinsulin

12:10

Lunch in Lobby

1:00

David Sacks, MB, ChB

NIH Clinical Center

Hemoglobin A1c as a Clinical Biomarker

1:35

Irl Hirsch, MD

University of Washington

Past, Present, and Future of T1D Biomarkers

2:10

Tai-Du Lin, PhD

PNNL

LC-MS Assays for Obesity Biomarkers

2:35

Michael MacCoss, PhD

University of Washington

Using Mass Spectrometry for Monitoring Patient Response to Therapy

3:00

Weijun Qian, PhD & Jun Qu, PhD

PNNL & University of Buffalo

Top-down Proteomics for Elucidating Cellular Prohormone Proteoforms and Novel Analytical Approaches for Enhancing Sensitivity